Pacira BioSciences' Cash from Operations rose 1282.27% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.4 million, marking a year-over-year decrease of 3061.41%. This contributed to the annual value of $189.4 million for FY2024, which is 2246.38% up from last year.
Latest data reveals that Pacira BioSciences reported Cash from Operations of $60.8 million as of Q3 2025, which was up 1282.27% from $12.0 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Cash from Operations ranged from a high of $60.8 million in Q3 2025 and a low of $12.0 million during Q2 2025
Its 5-year average for Cash from Operations is $38.1 million, with a median of $42.0 million in 2022.
Its Cash from Operations has fluctuated over the past 5 years, first surged by 29286.99% in 2021, then tumbled by 7743.63% in 2025.
Pacira BioSciences' Cash from Operations (Quarter) stood at $23.2 million in 2021, then surged by 81.08% to $42.0 million in 2022, then grew by 13.2% to $47.6 million in 2023, then crashed by 30.37% to $33.1 million in 2024, then surged by 83.61% to $60.8 million in 2025.
Its Cash from Operations was $60.8 million in Q3 2025, compared to $12.0 million in Q2 2025 and $35.5 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value